The National Health Service System in Korea, the data provider, requires all involved researchers to pledge not to share, release, or review the data with other entities (<http://nhiss.nhis.or.kr/down/%EC%84%9C%EC%95%BD%EC%84%9C.pdf>; in Korean). Any request regarding data and the study itself should be directed to the corresponding authors, who have signed the data release agreement form of the National Health Service System in Korea. In addition, it is possible for other researchers to request access to the data directly from the National Health Insurance System via instruction at following URLs: <https://nhiss.nhis.or.kr/bd/ab/bdaba001cv.do>; <https://nhiss.nhis.or.kr/bd/ay/bdaya003iv.do?LR>.

Introduction {#sec001}
============

Type 2 diabetes mellitus (T2DM) is one of the most prevalent chronic metabolic disorders, typically requiring life-long management. The global number of patients with T2DM increased from 108,000,000 in 1980 to 422,000,000 in 2014, and the prevalence among adults aged ≥ 18 years almost doubled from 4.7% in 1980 to 8.5% in 2014 \[[@pone.0210159.ref001]\]. Additionally, the number of individuals with diabetes is expected to increase from 425,000,000 in 2017 to 629,000,000 in 2045 globally, and \~90% of the cases are T2DM \[[@pone.0210159.ref002]\]. In Korea, the financial and societal burdens of T2DM are also substantial; the prevalence rate of diabetes among adults \> 30 years was 14.4% in 2016 \[[@pone.0210159.ref003]\], while the cost of medical therapy increased almost six-fold from 82,500,000 USD in 2002 to 480,000,000 USD in 2013 \[[@pone.0210159.ref004]\]. Patients with T2DM have a high risk of developing macrovascular and microvascular complications if the disease is not adequately controlled \[[@pone.0210159.ref005]\]. For example, T2DM is the main cause of chronic kidney disease globally, while diabetic nephropathy develops in 25--40% of patients with diabetes \[[@pone.0210159.ref006],[@pone.0210159.ref007]\]. In addition, diabetic neuropathy is the most common cause of neuropathy in developed countries, and up to 50% of patients have neuropathy that causes major complications, including diabetic foot and infection \[[@pone.0210159.ref008]--[@pone.0210159.ref010]\].

Various oral antidiabetic drugs have been developed to control T2DM. The treatment guideline for T2DM in South Korea is the same as the America Diabetes Association guideline. Guidelines in both Korea and the U.S. diagnose T2DM as follows: 1) HbA1C ≥ 6.5%; 2) fasting plasma glucose ≥126 mg/dL (7.0 mmol/L); 3) 2 h plasma glucose value after 75 g oral glucose ≥ 200 mg/dL (11.1 mmol/L); or 4) diabetic symptom and random plasma glucose ≥ 200 mg/dL \[[@pone.0210159.ref011]\]. Both guidelines also state that the purpose of treatment of T2DM is to maintain HbA1c \< 6.5% \[[@pone.0210159.ref005],[@pone.0210159.ref012]\]. The treatment is started with metformin when the HbA1c level is \< 7.5%. A second oral antidiabetic agent or insulin can be added if metformin monotherapy is ineffective in 3 months or if Hb1Ac is \> 7.5% \[[@pone.0210159.ref005],[@pone.0210159.ref012]--[@pone.0210159.ref015]\]. However, insulin can be started as the first treatment when patients with newly diagnosed diabetes have hyperglycemic and metabolic symptoms with HbA1c \> 9.0% \[[@pone.0210159.ref015]\]. In this case, inadequate glucose control usually drives the prescribing of insulin, leading to the assumption that insulin use indicates advanced T2DM \[[@pone.0210159.ref005],[@pone.0210159.ref012],[@pone.0210159.ref014],[@pone.0210159.ref016]\].

The prevalence of diabetes has increased most rapidly in low- and middle-income countries compared with high-income countries \[[@pone.0210159.ref001]\]. According to a national diabetes statistics report in the U.S., the prevalence and incidence of T2DM was higher in individuals with lower levels of education, which may be associated with a low income \[[@pone.0210159.ref017]\]. Studies have also shown poorer health status and lower healthcare usage among individuals on a low income than among those on a high income, indicating that those with a low income may have inadequate access to healthcare services and as a result may be at an increased health risk \[[@pone.0210159.ref018]--[@pone.0210159.ref021]\]. The relationships between income and diabetes prevalence have been reported in Korea and Asian countries as well \[[@pone.0210159.ref022]--[@pone.0210159.ref027]\]. However, no studies have been performed to investigate the relationship between income and insulin use in Asia. The present study aimed to assess the use of insulin in patients with newly diagnosed T2DM and to investigate the difference in diabetic management, focusing particularly on the role of their economic status on insulin use.

We also assessed whether access to primary physicians, operationally defined as the frequently used medical care providers at the time of T2DM diagnosis (frequently-visited physician, hereafter) was associated with insulin use. The positive effect of primary physicians in the management of chronic disease, including T2DM, is well recognized in the literature. For example, previous studies in the U.S. have shown that primary physicians had a positive impact on the management of diabetes \[[@pone.0210159.ref028],[@pone.0210159.ref029]\]. Interventions by primary physicians have also been reported to improve clinical outcomes in patients with chronic diseases, including hypertension and chronic pain \[[@pone.0210159.ref030],[@pone.0210159.ref031]\]. However, no studies on frequently-visited physicians and insulin use have been performed in Korea. The present study may be useful for understanding the implicit role of frequently-visited physicians in the management of diabetes in Korea.

Materials and methods {#sec002}
=====================

Data {#sec003}
----

We used insurance claim data from the National Health Insurance Service (NHIS), which provides public health insurance to all legal residents in Korea. All clinics, hospitals, and pharmacies in Korea are required to participate in the NHIS, and they are reimbursed for their services through the NHIS after filing claims electronically. Using these data meant the research was relevant in a real-world context with a nationally representative cohort, providing useful evidence for establishing a national-level management system for T2DM. This study was based on retrospective NHIS data, and all data were anonymized. The study was approved by the Research Ethics Committees of Yonsei University (7001988-201704-HR-175-01E), and informed consent was waived by the IRB.

We retrospectively obtained the data of 1,000,000 respondents, which was approximately 2% of a total random sample from the NHIS data, for the period 2002--2012. During this time, 294,610 patients were diagnosed with T2DM or a diabetes-related disease based on the International Statistical Classification of Diseases and Related Health Problems, 10^th^ revision (ICD-10). The following codes were used to identify target patients: E11 (T2DM), E12 (malnutrition-related diabetes), E13 (other specified diabetes), E14 (unspecified diabetes), G590 (diabetic mononeuropathy), G632 (diabetic polyneuropathy), H280 (diabetic cataract), H360 (diabetic retinopathy), M142 (diabetic arthropathy), N083 (diabetic nephropathy), O24 (gestational diabetes), R73 (hyperglycemia), R81 (glycosuria), and Z131 (special screening test for diabetes).

Any patients who succumbed to mortality between 2002 and 2012 (N = 29,471) were excluded. The T2DM codes may have been entered when blood glucose was temporally elevated, however, this does not necessarily mean that the patients are diagnosed as DM. Therefore, various exclusion criteria were applied to reduce false-positives for T2DM. The following exclusion criteria were also applied to restrict the sample to patients who were newly diagnosed with T2DM: 1) diagnosed with DM in 2002 (the initial year of the cohort) (N = 32,446); and 2) prescribed or administered with antidiabetic drugs preceding the diagnosis of DM (N = 2,414). Patients who were diagnosed with type 1 DM (N = 1,315) and were \< 20 years old (N = 16,562) were also excluded. Finally, patients who attended hospitals or clinics for DM treatment on fewer than three occasions within a given year were also excluded (N = 120,592). The final sample included 91,810 adult patients ([Fig 1](#pone.0210159.g001){ref-type="fig"}). Focusing on patients who were newly diagnosed with T2DM provides a more valid assumption that insulin use for the newly-diagnosed patients implies poor management of T2DM. In addition, as it was not possible to identify when T2DM was diagnosed for patients who were diagnosed with diabetes before baseline in the present study, the underlying reason for insulin use cannot be rightfully assumed \[[@pone.0210159.ref032],[@pone.0210159.ref033]\].

![Selection of study sample.](pone.0210159.g001){#pone.0210159.g001}

Dependent variable {#sec004}
------------------

The pattern of antidiabetic drug use was considered the dependent variable and was defined as follows: 1) non-use of antidiabetic drugs, 2) prescription of oral antidiabetic drugs only, or 3) prescription of insulin with or without oral antidiabetic drugs. Insulin prescription or use was considered to indicate advanced T2DM, consistent with previous studies \[[@pone.0210159.ref005],[@pone.0210159.ref012]--[@pone.0210159.ref014]\].

Independent variables {#sec005}
---------------------

The main independent variables were health insurance premium and access to a frequently-visited physician. The patients were identified as having a frequently-visited physician if they visited the same clinic or hospital for \>90% of all their claims within a 1-year period at the time of T2DM diagnosis. NHIS premiums were classified into five levels, with the reference group as the most affluent. In Korea, this premium is determined based on the earnings and assets of a given household, and naturally there is no differential for healthcare access or out-of-pocket expenses for insured services by premium or income levels. Approximately 4--5% of Koreans are under Medical-aid system, similar to the Medicaid program in the U.S., which waivers premium and the majority of out-of-pocket payments. Patients are able to choose any clinic or general hospital regardless of insurance status. Referral letters are required for first time users of general hospitals, for which the coinsurance rate for out-of-pocket payment is higher than clinics or non-general small hospitals with less than five specialisms \[[@pone.0210159.ref034]\]. Only for Medical-aid patients clinics are designated when there are risks of too frequent medical visits or drug abuse, and they require a letter from the designated providers to use other clinics or upper level hospitals \[[@pone.0210159.ref035]\].

The following covariates were controlled for all estimations: age, sex, insurance qualification, prescriber characteristics, Charlson comorbidity index (CCI), residential area, and year of diagnosis. Age was classified into three categories \[≤ 34 years, ≥ 35 years but \< 65 years, and ≥ 65 years (reference group)\]. The insurance qualification was divided into the main beneficiaries and dependents. Prescriber characteristics included type \[i.e., general teaching hospitals, general hospitals, and clinics (reference group)\] and specialty \[i.e., family medicine, others, and internal medicine (reference group)\]. The comorbidities of the respondents were weighted to generate the CCI, an index used to predict the estimated 10-year survival rate of patients with various clinical conditions \[[@pone.0210159.ref036]\]. The CCI score was capped at 4, generating five possible classifications (0, 1, 2, 3, and ≥ 4). The year of diagnosis was generated as a series of dummy indicators.

Statistical analysis {#sec006}
--------------------

Multivariate Cox proportional hazards analysis was performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). The hazard ratios (HRs) and 95% of confidence intervals (CIs) were calculated for each variable. The level of significance was set at a p-value of 5%.

Results {#sec007}
=======

Summary statistics {#sec008}
------------------

The demographic data for the final sample are summarized in [Table 1](#pone.0210159.t001){ref-type="table"}. The results revealed that over half (53.9%) of the sample (91,810 adults) did not use any antidiabetic drugs, whereas approximately one-third (36.3%) used oral antidiabetic drugs and one-tenth (10.1%) used insulin. The sample included marginally more female than male patients, and although the majority of patients were aged 35--64 years, over a third of the sample was aged ≥ 65 years.

10.1371/journal.pone.0210159.t001

###### Distribution according to the utilization pattern of antidiabetic drugs[^a^](#t001fn001){ref-type="table-fn"}.

![](pone.0210159.t001){#pone.0210159.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                       Total\           No antidiabetic drug group\   Oral antidiabetic drug group\   With insulin group\
                                                 (N = 91,810)     (N = 49,151)                  (N = 33,378)                    (N = 9,281)
  ---------------------------------------------- ---------------- ----------------------------- ------------------------------- ---------------------
  Sex                                                                                                                           

      Male                                       44,604 (48.58)   20,931 (42.59)                18,670 (55.94)                  5,003 (53.91)

      Female                                     47,206 (51.42)   28,220 (57.41)                14,708 (44.06)                  4,278 (46.09)

  Age, years                                                                                                                    

      20--34                                     5,671 (6.18)     4,087 (8.32)                  937 (2.81)                      647 (6.97)

      35--64                                     59,654 (64.98)   29,448 (59.91)                23,957 (71.77)                  6,249 (67.33)

      ≥65                                        26,485 (28.85)   15,616 (31.77)                8,484 (25.42)                   2,385 (25.70)

  Health insurance premium levels                                                                                               

      Medical-aid group                          5,185 (5.65)     2,504 (5.09)                  1,965 (5.89)                    716 (7.71)

      Levels 1--4                                24,823 (27.04)   12,678 (25.79)                9,379 (28.10)                   2,766 (29.80)

      Levels 5--7                                24,425 (26.60)   12,964 (26.38)                8,915 (26.71)                   2,546 (27.43)

      Levels 8 and 9                             22,739 (24.77)   12,534 (25.50)                8,110 (24.30)                   2,095 (22.57)

      Level 10                                   14,638 (15.94)   8,471 (17.23)                 5,009 (15.01)                   1,158 (12.48)

  Presence of frequently-visited physicians                                                                                     

      No                                         78,658 (85.67)   44,327 (90.19)                27,046 (81.03)                  7,285 (78.49)

      Yes                                        13,152 (14.33)   4,284 (9.81)                  6,332 (18.97)                   1,996 (21.15)

  Insurance qualification                                                                                                       

      Main beneficiaries                         46,126 (50.24)   26,361 (53.63)                15,246 (45.68)                  4,519 (48.69)

      Dependents                                 45,684 (49.76)   22,790 (46.37)                18,132 (54.32)                  4,762 (51.31)

  Types of healthcare providers upon diagnosis                                                                                  

      Clinics                                    50,572 (55.08)   24,391 (49.62)                21,681 (64.96)                  4,500 (48.49)

      General hospitals                          11,348 (12.36)   6,241 (12.70)                 3,776 (11.31)                   1,331 (14.34)

      General teaching hospitals                 29,890 (32.56)   18,519 (37.68)                7,921 (23.73)                   34,50 (37.17)

  Medical specialty of the physicians                                                                                           

      Internal medicine                          61,344 (66.82)   30,106 (61.25)                24,888 (74.56)                  6,350 (68.42)

      Family medicine                            6,106 (6.65)     2,654 (5.40)                  2,917 (8.74)                    535 (5.76)

      Others                                     24,360 (26.53)   16,391 (33.35)                5,573 (16.70)                   2,396 (25.82)

  Residential area                                                                                                              

      Big cities                                 42,464 (46.25)   22,906 (46.60)                15,393 (46.12)                  4,165 (44.88)

      Small- and medium-sized cities             39,754 (43.30)   21,253 (43.24)                14,506 (43.46)                  3,995 (43.04)

      Rural area                                 9,592 (10.45)    4,992 (10.16)                 3,479 (10.42)                   1,121 (12.08)

  Charlson comorbidity index scores                                                                                             

      0                                          24,101 (26.25)   15,135 (30.79)                7,154 (21.43)                   1,812 (19.52)

      1                                          33,634 (36.63)   18,689 (38.02)                12,154 (36.41)                  2,791 (30.07)

      2                                          21,859 (23.81)   10,728 (21.83)                8,733 (26.16)                   2,398 (25.84)

      3                                          8,456 (9.21)     3,339 (6.79)                  3,696 (11.07)                   1,421 (15.31)

      ≥4                                         3,760 (4.10)     1,260 (2.56)                  1,641 (4.92)                    859 (9.26)

  Year of diagnosis                                                                                                             

      2003                                       6,278 (6.84)     2,033 (4.14)                  2,801 (8.39)                    1,444 (15.56)

      2004                                       6,211 (6.77)     2,391 (4.86)                  2,706 (8.11)                    1,114 (12.00)

      2005                                       7,515 (8.19)     3,364 (6.84)                  3,047 (9.13)                    1,104 (11.90)

      2006                                       6,219 (6.77)     2,753 (5.60)                  2,649 (7.94)                    817 (8.80)

      2007                                       7,342 (8.00)     3,585 (7.29)                  2,970 (8.90)                    787 (8.48)

      2008                                       7,925 (8.63)     3,822 (7.78)                  3,218 (9.64)                    885 (9.54)

      2009                                       8,462 (9.22)     4,415 (8.98)                  3,268 (9.79)                    779 (8.39)

      2010                                       8,932 (9.73)     5,114 (10.40)                 3,194 (9.57)                    624 (6.72)

      2011                                       13,090 (14.26)   7,913 (16.10)                 4,291 (12.86)                   886 (9.55)

      2012                                       10,962 (11.94)   7,492 (15.24)                 2,965 (8.88)                    505 (5.44)

      2013                                       8,874 (9.67)     6,269 (12.75)                 2,269 (6.80)                    336 (3.62)
  ---------------------------------------------------------------------------------------------------------------------------------------------------

^a^Data are presented as number of subjects and percentage.

Distribution for each independent variable had a significant difference among the no antidiabetic drug group, oral antidiabetic group, and with insulin group at a 5% significance level.

The proportion of Medical-aid patients was higher in the group that used insulin (7.71%) than in the groups that used no antidiabetic drugs (5.08%) or oral antidiabetic drugs only (5.89%) (P \< 0.0001). The majority of patients with T2DM did not have frequently-visited physicians (85.67%), while approximately half of the patients were diagnosed with T2DM in clinics (55.08%), whereas fewer were diagnosed in general hospitals (12.36%) or general teaching hospitals (32.56%). Over half of the patients (66.82%) were diagnosed with T2DM by internal medicine specialists. Patients who were using insulin had a significantly higher CCI (9.26% in patients with CCI ≥ 4) compared with those in the non-use of antidiabetic drug group (2.56%) and the oral antidiabetic drug group (4.92%) (P \< 0.0001). Further analysis showed that the higher CCI score among the Medical-aid group than the higher income group was persistently found, not only among patients in the insulin use group (9.8% vs. 9.2%, P \< 0.0001) but also in patients in the oral antidiabetic drug group (5.7% vs. 4.8%, P \< 0.0001) and those in the non-use of antidiabetic drug T2DM group (3.7% vs. 2.5%, P \< 0.0001).

Time to start insulin {#sec009}
---------------------

The time to start insulin use was defined as the period from the day of diagnosis to the day of the first insulin prescription. [Table 2](#pone.0210159.t002){ref-type="table"} shows the results based on the patient's health insurance premium and access to a frequently-visited physician. The mean time to starting insulin was 830.47 days overall, although the time decreased as the health insurance premium decreased, falling to a mean time of only 490.66 days in the Medical-aid group. The differences between the groups were significant. Patients with a frequently-visited physician tended to have delayed times to starting insulin (average 864.34 days) compared to those without a frequently-visited physician (average 821.18 days), although this was only marginally significant (P = 0.0935). However, Medical-aid patients without a frequently-visited physician had a significant delay to initiating insulin (average 537.97 days) compared to patients with frequently-visited physicians (average 419.51 days) (P \< 0.0001).

10.1371/journal.pone.0210159.t002

###### Time to start insulin use in the insulin-treated group.

![](pone.0210159.t002){#pone.0210159.t002g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Group                                                                           Number of participants   Duration time to insulin use (days):\   P-value
                                                                                                           mean (SD)                               
  ------------------------------------------------------------------------------- ------------------------ --------------------------------------- ---------
  Total                                                                           9281                     830.47 (987.03)                         

  Health Insurance premium levels                                                 \<0.0001                                                         

      Medical-aid group                                                           716                      490.66 (621.03)                         

      Levels 1--4                                                                 2766                     854.96 (987.99)                         

      Levels 5--7                                                                 2546                     819.57 (996.21)                         

      Levels 8 and 9                                                              2095                     876.29 (1017.39)                        

      Level 10                                                                    1158                     923.10 (1049.33)                        

  Presence of frequently-visited physicians                                       0.0935                                                           

      No                                                                          7285                     821.18 (991.07)                         

      Yes                                                                         1996                     864.34 (971.65)                         

  Presence of frequently-visited physicians and health insurance premium levels                                                                    

      With frequently-visited physicians                                                                                                           

          Health insurance premium levels                                         \<0.0001                                                         

              Medical-aid group                                                   286                      419.51 (655.70)                         

              Levels 1--4                                                         2207                     838.92 (984.95)                         

              Levels 5--7                                                         2068                     797.86 (992.08)                         

              Levels 8 and 9                                                      1747                     841.30 (999.88)                         

              Level 10                                                            977                      912.09 (1039.76)                        

      Without frequently-visited physicians                                                                                                        

          Health insurance premium levels                                         \<0.0001                                                         

              Medical-aid group                                                   430                      537.97 (592.93)                         

              Levels 1--4                                                         559                      918.30 (998.28)                         

              Levels 5--7                                                         478                      913.50 (1009.58)                        

              Levels 8 and 9                                                      348                      1051.95 (1085.65)                       

              Level 10                                                            181                      982.52 (1100.64)                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

Survival analysis {#sec010}
-----------------

Survival analysis was performed to assess the relationship between patient characteristics and insulin use ([Table 3](#pone.0210159.t003){ref-type="table"}). Insulin use tended to increase (P \< 0.0001) as income decreased. Insulin was used \~2.8 times more often in the Medical-aid group than in the highest premium group (HR: 2.874, 95% CI: 2.588--3.192). Additionally, patients with a frequently-visited physician were more likely to use insulin (HR: 1.549, 95% CI: 1.434--1.624).

10.1371/journal.pone.0210159.t003

###### Overall survival analysis[^a^](#t003fn001){ref-type="table-fn"}.
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  Independent variable                        Dependent variable: Insulin use                  
  ------------------------------------------- --------------------------------- -------------- ----------
  Health insurance premium levels                                                              
      Medical-aid group                       2.874                             2.588--3.192   \<0.0001
      Levels 1--4                             1.485                             1.385--1.592   
      Levels 5--7                             1.338                             1.247--1.435   
      Levels 8 and 9                          1.202                             1.118--1.292   
      Level 10 (reference)                    \-                                \-             
  Access to a frequently-visited physicians                                                    
      Yes                                     1.549                             1.470--1.631   \<0.0001
      No (reference)                          \-                                \-             
      N                                       91,810                                           

^a^Other covariates that were controlled for included age, sex, insurance qualification, prescriber characteristics, Charlson comorbidity index, residential area, and year of diagnosis.

Survival analyses were performed for subgroups based on access to frequently-visited physicians and the level of health insurance (Tables [4](#pone.0210159.t004){ref-type="table"} and [5](#pone.0210159.t005){ref-type="table"}). The magnitude of the negative income gradient on the likelihood of insulin use (i.e., the higher likelihood of insulin use, the lower income group) became more apparent in patients who had access to a frequently-visited physician than in those without access (P \<0.0001). Patients who received Medical-aid and with access to a frequently-visited physician were \~3.8 times more likely to be prescribed insulin than patients paying the highest premium level (HR: 3.798, 95% CI: 3.094--4.663); in contrast, this difference was 2.3 times higher for patients who received Medical-aid and had no access to a frequently-visited physician (HR: 2.286, 95% CI: 1.986--2.630) (upper panel of [Table 4](#pone.0210159.t004){ref-type="table"}). Survival analysis by health insurance premium also indicated that insulin use was more likely among patients from lower income groups who had access to a frequently-visited physician. In the Medical-aid group, patients with a frequently-visited physician were \~71% more likely to use insulin than those without a frequently-visited physicians (HR: 1.715, 95% CI: 1.461--2.013), accounting for a difference of 41% in the highest premium group (HR: 1.416, 95% CI: 1.203--1.668).

10.1371/journal.pone.0210159.t004

###### Subgroup survival analysis based on frequently-visited physicians access[^1^](#t004fn001){ref-type="table-fn"}.
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  ----------------------------------------------------------------------------------------------------------------
  Independent variable\             Dependent variable: insulin use                                     
  (upper panel)\                                                                                        
  --------------------------------- --------------------------------- ---------------- ---------------- ----------
  Health insurance premium levels                                                                       

      Medical-aid                   3.798\                            \<0.0001         2.286\           \<0.0001
                                    (3.094--4.663)                                     (1.986--2.630)   

      Levels 1--4\                  1.567\                            1.476\                            
                                    (1.323--1.857)                    (1.367--1.593)                    

      Levels 5--7\                  1.458\                            1.317\                            
                                    (1.227--1.734)                    (1.219--1.422)                    

      Levels 8 and 9\               1.292\                            1.185\                            
                                    (1.079--1.547)                    (1.096--1.282)                    

      Level 10 (reference)          \-                                \-                                
  ----------------------------------------------------------------------------------------------------------------

^1^Other covariates that were controlled for included age, sex, insurance qualification, prescriber characteristics, Charlson comorbidity index, residential area, and year of diagnosis.

^a^ HR, hazard ratio; CI, confidence interval.

10.1371/journal.pone.0210159.t005

###### Subgroup survival analysis based on health insurance premium[^1^](#t005fn001){ref-type="table-fn"}.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Independent variable                        Subgroups in terms of health insurance premium levels                                                      
  ------------------------------------------- ------------------------------------------------------- ---------------- ---------------- ---------------- ----------------
  Presence of frequently-visited physicians                                                                                                              

      Yes\                                    1.715\                                                  1.441\           1.509\           1.543\           1.416\
                                              (1.461--2.013)                                          (1.311--1.585)   (1.363--1.671)   (1.371--1.736)   (1.203--1.668)

      No (reference)                          \-                                                      \-               \-               \-               \-
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^Other covariates that were controlled for included age, sex, insurance qualification, prescriber characteristics, Charlson comorbidity index, residential area, and year of diagnosis.

^a^ HR, hazard ratio; CI, confidence interval.

Discussion {#sec011}
==========

We assessed the current state of T2DM management in Korea, focusing on the use of insulin based on NHIS claim data. We also evaluated the differences in insulin use based on the economic status and access to a frequently-visited physician. The results showed that insulin use increased as the health insurance premium decreased. Those with a low income are less likely to be aware of their health conditions as a result of the difficulty obtaining a regular health check-up \[[@pone.0210159.ref018],[@pone.0210159.ref037]--[@pone.0210159.ref039]\], therefore, they are more likely to visit clinics or hospitals after they experience symptoms of diabetes. If T2DM management is inadequate at the early stages, it can quickly worsen and potentially increase the rates of early insulin use. As T2DM has already progressed, low-income patients are likely to start insulin after diagnosis. Insulin is used when HbA1c is \> 9.0%, or when metformin is ineffective. According to Korea Diabetes Fact Sheet 2018, only 60% of diabetes patients recognized that they had diabetes, and 43.1% patients who had diabetes were not treated in Korea \[[@pone.0210159.ref003]\]. In Japan, \~ 35% of patients strongly suspected of having diabetes were not treated \[[@pone.0210159.ref040],[@pone.0210159.ref041]\]. In addition, the time to insulin use was 1.34 years among all Medical-aid patients and increased to 1.47 years among Medical-aid patients without access to a frequently-visited physician. These were notably shorter than the usual lag time of 10--15 years when using a traditional stepwise strategy \[[@pone.0210159.ref042]\].

Our finding that insulin use started earlier for patients with a low income is consistent with that of previous reports. A study in the United Kingdom showed that multi-morbidities, including diabetes, developed 10--15 years earlier in regions with the lowest incomes compared with regions with the highest incomes \[[@pone.0210159.ref018]\]. A systematic review also showed that low income is associated with an increased risk of T2DM \[[@pone.0210159.ref043]\]. Several studies in Asian countries have reported similar findings. For example, a study in Hong Kong showed that the lower income group had a higher risk of diabetes and poorer prognosis than the higher income group \[[@pone.0210159.ref044]\]. A study in China also showed that patients with a lower income had a higher incidence of diabetic retinopathy and neuropathy \[[@pone.0210159.ref045]\], indicating either poor or non-timely management of diabetes. A study in Taiwan using the National Health Insurance Research Database also estimated that the incidence of T2DM was higher in the those with a lower income, who were also less likely to visit diabetes clinics \[[@pone.0210159.ref046]\]. Studies in Japan have also reported that those with a low income had a higher incidence of T2DM and higher T2DM treatment rate \[[@pone.0210159.ref026],[@pone.0210159.ref047]\].

Another interesting finding in the present study was that the majority of patients did not have a frequently-visited physician. It may be that frequently-visited physician system has not been legislated in Korea, resulting in a lack of familiarity of the concept of frequently-visited physicians with no enforcement. The likelihood of insulin use was also higher in the Medical-aid group when patients had frequently-visited physicians than when they did not in the present study, which ironically indicated that access to a frequently-visited physician at the time of T2DM diagnosis improves management of the condition. Using insulin may be dangerous without appropriate vigilance as it can lead to severe hypoglycemia \[[@pone.0210159.ref048]\]. Therefore, frequently-visited physicians could base care for T2DM on the clinical status of their patients in a more timely manner \[[@pone.0210159.ref049]\], starting insulin use without necessarily offering oral antidiabetic drugs if their clinical diagnosis shows progression of T2DM warranting insulin \[[@pone.0210159.ref005]\]. Consistent with this, a cross-sectional online survey showed that \> 80% of insulin use was initiated by primary physicians \[[@pone.0210159.ref050]\]. Communication between physician and patients can improve adherence to medication \[[@pone.0210159.ref051]\], thus frequent interactions between the patient and the frequently-visited physicians can reduce the reluctance to use insulin. Taken together, these findings suggest that T2DM among low-income patients can be managed more effectively with constant support by a frequently-visited physician.

The positive effects of appropriate management by primary physicians have been investigated in terms of the outcomes and prevention of complications among patients with chronic diseases, including diabetes \[[@pone.0210159.ref028]--[@pone.0210159.ref030]\]. The quality of medical care for patients with T2DM improved as the ratio of primary physicians increased \[[@pone.0210159.ref028]\], while patients with T2DM who had primary physicians also experienced improved outcomes following intensive medication and lifestyle counseling \[[@pone.0210159.ref029]\]. Several studies have also shown improved glycemic control when diabetic patients were under continuous care, and this continuous care was better with access to a primary care physicians \[[@pone.0210159.ref052],[@pone.0210159.ref053]\]. Additionally, primary care physicians provide superior care though lifestyle counseling and improved medical treatment \[[@pone.0210159.ref029]\], and frequent visits to a physician have been shown to achieve HbA1c targets faster in patients with diabetes \[[@pone.0210159.ref054]\].

However, few studies have identified the impact of care by primary physicians on patient outcomes in Asia, where the system for primary care is not yet well established \[[@pone.0210159.ref055],[@pone.0210159.ref056]\]. Previous studies in Korea and Japan have reported that patients consider specialists and larger hospitals to provide better services and outcomes, despite the extra cost and effort \[[@pone.0210159.ref055],[@pone.0210159.ref057],[@pone.0210159.ref058]\]. In the present study, primary physicians were defined on the basis of visit frequency in the absence of clear distinction in Korea. When patients with T2DM attended clinics more regularly to see a frequently-visited physician, the timeliness of management decisions may have been improved. There is a 'Chronic Disease Management System in Clinics' in Korea, in which the NHIS reduces the coinsurance rate of the out-of-pocket cost from 30% to 20% if patients with T2DM designate a particular clinic for long-term management \[[@pone.0210159.ref059]\]. By encouraging patients to visit the clinic regularly, early diagnosis and treatment of diabetes is made easier. Such persistent management of T2DM regularly by a gate-keeping physician could reduce cardiovascular risks, blindness, kidney failure, amputation, and depression \[[@pone.0210159.ref060],[@pone.0210159.ref061]\]. Therefore, it is necessary to intensify check-ups and increase the education of patients who already have diabetes based on the results. Currently, the Korean Diabetes Association is also advocating the benefits of insurance through counseling for diabetes education and expansion of the diabetes prevention program \[[@pone.0210159.ref062]\]. Our results offer real-world evidence to support the effectiveness and importance of regular management of T2DM, as the Korean Diabetes Association and Korean NHIS promote.

There are a number of strengths to the present study. First, our estimations were based on the claims data of the NHIS, which is a public health insurance that covers all legal residents of Korea. Therefore, our results are considered to be nationally representative. Second, we focused on the insulin use of newly diagnosed patients, which could implicitly indicate the extent of T2DM advancement. We did not include insulin use in inpatients admitted for emergency or ward care, making it possible to exclude shock and other emergency situations that can be accompanied by increased blood sugar levels requiring insulin treatment \[[@pone.0210159.ref063]\]. However, we acknowledge several caveats of the present study. First, uninsured medications were not included in NHIS claims despite the majority of antidiabetic drugs being covered by the NHIS \[[@pone.0210159.ref064]\]. Second, neither the true severity of T2DM nor whether patients took medicines can be accurately measured on the basis of insurance claims data.

Cohort data with detailed medical information on T2DM and patient socioeconomic characteristics would advance current understanding on diabetes treatment patterns by patients' socioeconomic conditions. Further information on the patient-physician relationship, including the duration of the relationship, would assist in establishing an effective primary care physician system, particularly where such system is not currently in place. In addition, the relationship between the frequency of regular check-ups and the management of T2DM may provide evidence on the importance of regular check-ups.

Conclusions {#sec012}
===========

Patients with low levels of income, as defined based on their level of health insurance, were more likely to use insulin and to have a short lag time before insulin therapy was started. The likelihood of insulin use was higher if a patient had access to a frequently-visited physician than if they did not, particularly if they also had a low income. Therefore, we conclude that a patient's economic status requires consideration when seeking to provide effective treatment for T2DM. Utilizing frequently-visited physicians might improve the management of this chronic disease, particularly among patients with a low income.
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